scispace - formally typeset
K

Khitam Muhsen

Researcher at Tel Aviv University

Publications -  131
Citations -  5969

Khitam Muhsen is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 27, co-authored 114 publications receiving 4523 citations. Previous affiliations of Khitam Muhsen include Centers for Disease Control and Prevention & University of Maryland, Baltimore.

Papers
More filters
Journal ArticleDOI

Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.

TL;DR: Interventions targeting five pathogens can substantially reduce the burden of moderate-to-severe diarrhoea and suggest new methods and accelerated implementation of existing interventions (rotavirus vaccine and zinc) are needed to prevent disease and improve outcomes.
Journal ArticleDOI

Helicobacter pylori Infection and Iron Stores: A Systematic Review and Meta‐analysis

TL;DR: A systematic literature review and meta‐analysis was carried out to evaluate the existing evidence on the association between Helicobacter pylori infection and iron stores.
Journal ArticleDOI

The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS).

TL;DR: The enormous African/Asian Cryptosporidium disease burden warrants investments to develop vaccines, diagnostics and therapies.
Journal ArticleDOI

A Systematic Review and Meta-analysis of the Association Between Giardia lamblia and Endemic Pediatric Diarrhea in Developing Countries

TL;DR: In this systematic review and meta-analysis, Giardia lamblia was not associated with acute pediatric diarrhea in nonindustrialized settings but was positively linked to persistent diarrhea.
Journal ArticleDOI

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data.

TL;DR: The effectiveness of the BNT162b2 vaccine in preventing SARS-CoV-2 infection and COVID-19-related hospitalization and mortality is comparable to the one reported in the phase III clinical trial.